Latest News

Siponimod – new data in SPMS


Click here to take the SPMS survey

Siponimod, the selective sphingosine-1-phosphate (S1P) receptor modulator (S1P1,5), produces a sustained reduction in worsening disability for up to five years in patients with secondary-progressive MS (SPMS), according to data submitted to the American Academy of Neurology annual meeting (Kappos et al. AAN 2020; abstract S40.003).

Read More